Salesforce (CRM) To Report Earnings Tomorrow: Here Is What To Expect
Customer relationship management software maker Salesforce (NYSE:CRM) will be reporting results tomorrow after market close. Here's what you need to know.
Salesforce missed analysts' revenue expectations by 0.5% last quarter, reporting revenues of $9.99 billion, up 7.6% year on year. It was a slower quarter for the company, with EPS guidance for next quarter missing analysts' expectations and a slight miss of analysts' annual recurring revenue estimates.
Is Salesforce a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting Salesforce's revenue to grow 6.8% year on year to $9.75 billion, slowing from the 10.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.55 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Salesforce has missed Wall Street's revenue estimates twice over the last two years.
Looking at Salesforce's peers in the sales software segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Freshworks delivered year-on-year revenue growth of 18.9%, beating analysts' expectations by 2.1%, and HubSpot reported revenues up 15.7%, topping estimates by 2%. Freshworks traded up 2.9% following the results while HubSpot was down 8.8%.
Read our full analysis of Freshworks's results here and HubSpot's results here.
There has been positive sentiment among investors in the sales software segment, with share prices up 9.4% on average over the last month. Salesforce is up 4.4% during the same time and is heading into earnings with an average analyst price target of $363.95 (compared to the current share price of $277.40).
Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Salesforce Beat Out IBM for $8 Billion Informatica Deal
International Business Machines (IBM, Financials) was among the bidders for Informatica (INFA, Financials) prior to the $8 billion acquisition by Salesforce (CRM, Financials), people familiar with the matter told Bloomberg. Though IBM ultimately did not close the deal, its involvement highlights the competitive bidding process for the cloud data management firm. Warning! GuruFocus has detected 5 Warning Sign with MSFT. Salesforce CEO Marc Benioff confirmed the competition in a recent interview, saying, We were lucky to be the winning bid. Informatica shares were little changed at $24.13 on Wednesday, while IBM rose 0.1% to $265.52, with a market cap near $247 billion. IBM's interest in Informatica aligns with its multiyear strategy to expand software and hybrid cloud offerings through acquisitions. The company previously acquired Red Hat for $34 billion in 2019, Apptio for $4.6 billion in 2023, and HashiCorp for $6.4 billion earlier this year. Informatica had also attracted interest from Cloud Software Group, Bloomberg previously reported. The deal solidifies Salesforce's data integration push as rivals compete more aggressively in enterprise software. This article first appeared on GuruFocus.
Business Insider
an hour ago
- Business Insider
OpenAI chairman's career advice? Remember what Eric Schmidt told Sheryl Sandberg about joining Google.
Bret Taylor, the chairman of OpenAI, believes that if you have the chance to attach yourself to success, you shouldn't let ego get in the way. "I think this is the quote I always heard, was Eric Schmidt to Sheryl Sandberg: 'If someone offers you a seat on a rocket ship, don't ask what seat,' you know? I like that philosophy of life," Taylor said on an episode of "Grit." At the time, Sandberg, who would famously later become Facebook's chief operations officer, was deciding whether or not to join a different tech company: Google. Google was a tiny fraction of the size in 2001, with fewer than 300 people. Eric Schmidt had recently been brought on by cofounders Sergey Brin and Larry Page to be CEO. Sandberg talked about her conversation with Schmidt during a speech to Harvard students. "So I sat down with Eric Schmidt, who had just become the CEO, and I showed him the spreadsheet and I said, this job meets none of my criteria," Sandberg recalled. "He put his hand on my spreadsheet and he looked at me and said, 'Don't be an idiot. Get on a rocket ship. When companies are growing quickly and they are having a lot of impact, careers take care of themselves. If you're offered a seat on a rocket ship, don't ask what seat. Just get on.'" Sandberg did end up taking the job, and joined as the general manager of Google's business unit, which had four people at the time. "I do think, especially in Silicon Valley, there's just unique moments, and you just have to be self-aware and aware of the market," OpenAI's Taylor said. Beyond being ready to jump at opportunity wherever it comes knocking at your door, remaining broadly flexible is also important, he added. "Most of the unhappiest people I know are rigidly following a plan and not observant of their own happiness or observant of the opportunities around them," Taylor said. "I actually think that a big part of life is recognizing when there's a unique opportunity that you didn't plan for, and asking yourself the question, ' Should I change my plans? ' Whether that's in your personal life or your professional life." Taylor's own career spans Big Tech and startups alike — from leading the team that helped create Google Maps and acting as co-CEO of Salesforce, to founding his own AI company, Sierra. "The idea of sitting on the sidelines, and drinking a mai tai on a beach, doesn't give me joy at all," he said. "I want to build." Just as Taylor was leaving Salesforce, ChatGPT was released. After a conversation over lunch with his cofounder, Clay Bavor, Taylor said the decision to start Sierra was set. But even if he wasn't heading this particular company, he added, he would still be working in an adjacent sphere. "I would be building open source software if not running a company right now, because I just want to work in the technology and help shape it," Taylor said. "Because it's the most exciting technology of my memory, and I want to play a part in shaping how we all use it." That's another key piece of Taylor's personal philosophy: being as involved as possible in shaping the trajectory of the world. "There's this Alan Kay quote: 'The best way to predict the future is to invent it.' And that is like, my operating principle," he said. "I want to impact the future, and I want to help invent it."
Yahoo
2 hours ago
- Yahoo
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Hims & Hers is gaining market share in the telehealth sector and has a long runway to disrupt the healthcare industry. It is acquiring a company in order to enter Europe. The stock is expensive, but it may still be a great investment over the long term. 10 stocks we like better than Hims & Hers Health › Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (NYSE: HIMS). Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, the company is taking a lot of share in the telehealth market. The stock has traded up 449% since going public, and it is up a staggering 158% in the past year. Disruptive innovation helped bring shareholders of Hims & Hers stock major gains. But does that make the stock a buy today? People in the United States get frustrated dealing with health insurance -- as you may know from personal experience. Hims & Hers aims to slowly disrupt the market with an innovative approach that bypasses insurers. It helps customers easily get generic medications that help deal with sexual health, hair loss, mental health, and other common concerns, by having prescriptions and shipments sent straight to their doors through monthly subscriptions. This model has helped Hims & Hers dominate the telehealth prescription market and reach $1.78 billion in trailing-12-month revenue. It's now trying to further expand its offerings by adding the branded weight loss drug Wegovy to its marketplace through a partnership with Novo Nordisk (NYSE: NVO). Previously, Hims & Hers sold weight loss drugs under an exemption because of supply shortages for the products, but with those shortages now resolved, it has to work with patent holders such as Novo Nordisk. Along with weight loss, it's also aiming to get into testosterone and menopause-related prescriptions. Today, Hims & Hers has 2.4 million active customers. Management believes there are over 100 million people who could utilize one of its products, giving the company a huge runway to grow. A key factor will be the new partnership for marketing Wegovy, which is an expensive subscription at an introductory discount offer of $549 a month. Usage of such drugs is growing like a weed, and could be a new growth avenue for Hims & Hers to pursue. Another huge step for Hims & Hers is international expansion. While countries vary in their approaches to healthcare and insurance, most people want easy-to-use products, affordable prices, and convenient at-home shipping regardless of where they live. Management hopes to supercharge international growth with its proposed buyout of competitor Zava in Europe. Zava serves the western European market with 1.3 million active customers in the United Kingdom, France, Germany, and Ireland. The combined company can utilize Hims & Hers' marketing expertise, increasing scale, and partnerships to bring this sought-after model to Europe. Global disruption of the healthcare space will give Hims & Hers an even larger runway for growth, while also allowing it to invest in new innovations -- including at-home patient testing and its own compounding manufacturing facility. Hims & Hers has grand ambitions to disrupt healthcare with its direct-to-consumer model, and Zava will give it even more scale to keep accelerating growth. It will be exciting to see what the combined company can do over the next decade. You can feel the excitement with Hims & Hers and its explosive revenue growth. Sales grew 111% year over year last quarter, and are expected to hit at least $2.3 billion in 2025. (They were just $100 million in 2020.) The company has a goal of reaching $6.5 billion in sales by 2030, which would make it one of the fastest-growing companies in the world this decade. This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, which is a high trailing earnings multiple even for a fast-growing company. However, revenue is growing so quickly and with such high margins that the company may grow into this high valuation by the end of the decade. As noted, management has a goal of $6.5 billion in revenue in 2030. With 20% bottom-line profit margins -- easily doable with 77% gross profit margin over the last 12 months -- that would equate to roughly $1.3 billion in annual earnings in 2030. Today, the market cap is $12.3 billion, which would mean a P/E of just around 9.5 by 2030 if the market cap did not change (which is an unlikely scenario, but demonstrates that there is potential for the valuation to drop). Even with some shareholder dilution that raises the number of shares outstanding, the stock would be trading at a P/E of around 10 to 12 at the current share price (which is also likely to change). If you believe this rapid growth will continue over the long term, Hims & Hers stock will grow into its valuation. If you have any doubts about this pace of growth, shares should be considered overvalued at the moment. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space was originally published by The Motley Fool
